ClinicalTrials.gg
CompletedNCT02422966Updated Jul 12, 2019

Paracetamol in Patent Ductus Arteriosus

A Phase 2 interventional study of Paracetamol and Ibuprofen in Ductus Arteriosus, Patent, sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.A. Completed at 5 sites in Italy. Open to participants aged 25 Weeks to 31 Weeks. Per ClinicalTrials.gov, last updated 2019-07-12.

Sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.A · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
25 Weeks to 31 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies testing acetaminophen in Ductus Arteriosus, Patent — 4 open to participants now, 4 under way, 1 of them phase 3. Acetaminophen · Ductus Arteriosus, Patent.

Enrollment
7th of 24
110 · median 68
Started
2015
with 1 other
Phase 2
8 of 24
2 open now
Registered
8th of 24
by date
Lead sponsor
1 of 24
Aziende Chimiche Riunite Angelini Francesco S.p.A

Among the 24 studies testing acetaminophen in Ductus Arteriosus, Patent, this one is the 7th largest by enrollment, is one of 2 that started in 2015, is one of 8 in phase 2, and was the 8th registered.

Ductus Arteriosus, Patent

146 studies on the registry are indexed under Ductus Arteriosus, Patent; 21 are open to participants now.

Browse Ductus Arteriosus, Patent studies →

Open to participants now

4 of the 24 studies testing acetaminophen in Ductus Arteriosus, Patent are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Ductus Arteriosus, Patent studies recruiting now, 4 (29%) set no upper age limit and 10 (71%) stop at 75 or younger; 14 take children under 18; 1 takes healthy volunteers.

This study: 25 Weeks to 31 Weeks · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing acetaminophen in Ductus Arteriosus, Patent, or all of them as a file.
02

Study summary

The purpose of the study is to assess the efficacy and safety of paracetamol in comparison to ibuprofen in the treatment of patent ductus arteriosus (PDA) in preterm infants.

Read the detailed description

Although patency of the ductus arteriosus is essential for fetal circulation, the postnatal ductal closure is critical for postnatal circulatory adaptation. In premature infants the circulating prostaglandin levels are higher than at term, and respiratory difficulties may lead to a state of hypoxia, which contribute to the failure of the ductus closure. Recently, an incidental finding in one preterm infant led to look at paracetamol, one of the most common drugs available, as an alternative therapeutic approach to ductal closure. If paracetamol is proven to be effective, it could become the treatment of choice for the management of PDA, mainly due to its more favorable safety profile.

Although the recent results available in the literature demonstrates an highly success rate in ductal closure with paracetamol, all case studies are not powered to show efficacy of paracetamol for PDA closure. Further prospective randomized-controlled trials are needed to evaluate the efficacy of paracetamol versus ibuprofen for the closure of PDA.

If paracetamol is indeed proven to be effective, it could become the treatment of choice for the management of PDA, mainly due to its more favorable side effect profile. In order to test this hypothesis, a randomized, open label, parallel groups, comparator controlled, multicentre, prospective study is proposed.

03

Conditions studied

  • Ductus Arteriosus, Patent
04

Who can participate

Ages eligible
25 Weeks to 31 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female preterm infants with no limitation of race.
  2. Gestational age 25(+0) - 31(+6) weeks.
  3. Age 24-72 hours.
  4. Echocardiographic evidence of hemodynamically significant patent ductus arteriosus at the first 24-72 hours of life.

    The diagnosis of hemodynamically significant PDA requiring treatment will be made by echocardiographic demonstration of a ductal left-to-right shunt, with a left atrium-to-aortic root ratio >1.3 or a ductal size >1.5 mm and excluding the cases in which the closing flow pattern suggests a restrictive PDA.

  5. Willingness of the parents/legally authorized representative/child to sign the Consent Informed Form.

Exclusion criteria

Exclusion Criteria:

  1. Outborn patients.
  2. Major congenital anomalies, including but not limited to congenital heart defects, Down syndrome newborn and/or new born suffering from congenital anomalies diagnosed during the fetal period.
  3. Known positive and/or known positive Virus newborn's mother.
  4. Life threatening infection, complicated or not by multiple organ dysfunction and failure syndrome.
  5. Fetal hydrops.
  6. Pulmonary hypertension diagnosed in the first 24-48 hours of life by means of heart ultrasound when the presence of a right-to-left shunt through the foramen ovale or ductus arteriosus is demonstrated, or when the estimated pulmonary pressure, in terms of the tricuspid regurgitation jet, is greater than two-thirds of the systemic arterial pressure.
  7. Grade 3 or 4 intraventricular haemorrhage (IVH).
  8. Urine output \<1 ml/kg of body weight/h during a 24 h collection period or urine output \<0.5 ml/kg of body weight/h in case it is measured at 24 hours of life of newborn.
  9. Serum creatinine concentration > 1.5 mg/dl (132 μmol/l).
  10. count \< 50,000/mm3.
  11. Major bleeding, as revealed by hematuria, or blood in the endotracheal aspirate, gastric aspirate, or stools, or consistent oozing of blood from puncture sites.
  12. Severe liver failure, defined as elevated liver enzymes (/Glutamate-Pyruvate Transaminase and Aspartate aminotransferase/GOT) > 2 times the upper boundary of the normal range. For this kind of population the following normal ranges will be considered [Rosenthal, 1997]:

    • ALT/Glutamate-pyruvate transaminase: 6-50 U/L
    • Aspartate aminotransferase/GOT: 35-140 U/L
  13. Medical need of administering other Nonsteroidal Antiinflammatory Drug (NSAID) different from ibuprofen.
  14. Participation to another trial involving any drug.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    Paracetamol

    Paracetamol intravenous solution 15 mg/kg (corresponding to 1.5 ml/kg) per dose every 6 hours for 3 days, for a total amount of 12 doses.

    Drug: Paracetamol

  • Active comparator
    Ibuprofen

    Ibuprofen intravenous solution at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 5 mg/kg at 48 h.

    Drug: Ibuprofen

Interventions

06

What researchers measure

Primary outcomes

  1. success rate in closing PDA using paracetamol in comparison to ibuprofen.

    assessed echocardiographically.

    Time frame: at Visit 3 (day 3).

Secondary outcomes

  1. number of re-openings.

    assessed echocardiographically.

    Time frame: at Follow-up 3 (day 30).

  2. success rate in closing PDA after the second treatment course of ibuprofen as rescue medication.

    assessed echocardiographically.

    Time frame: at Visit 6 (day 6).

  3. success rate of closing PDA after the first day of the first treatment course.

    assessed echocardiographically.

    Time frame: at Visit 1 (day 1).

  4. success rate of closing PDA after the second day of the first treatment course.

    assessed echocardiographically.

    Time frame: at Visit 2 (day 2).

  5. incidence of surgical ligation.

    Time frame: at Follow-up 3 (day 30).

  6. incidence of renal failure, liver failure and gastrointestinal complications (including isolated intestinal perforation).

    assessed by laboratory analysis.

    Time frame: at Follow-up 3 (day 30).

  7. incidence of death,

    Time frame: at Follow-up 3 (day 30).

  8. incidence of death.

    Time frame: at Follow-up 4 (40 weeks post-conception).

  9. incidence of sepsis.

    Time frame: at Follow-up 3 (day 30).

  10. hospital-stay duration in Neonatal Intensive Care Unit.

    Time frame: at Follow-up 4 (40 weeks post-conception).

  11. occurrence of adverse effects.

    Time frame: at Follow-up 3 (day 30).

07

Study locations

5 sites
  • Azienda Ospedaliero Universitaria Careggi - Neonatologia e Terapia Intensiva Neonatale
    Firenze, 50134, Italy
  • IRCCS "Giannina Gaslini" Genova - Patologia Neonatale e Terapia Intensiva Neonatale
    Genova, 16147, Italy
  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico U.O. di Neonatologia e Terapia Intensiva Neonatale
    Milano, 20122, Italy
  • Azienda Ospedaliera Istituti Clinici di Perfezionamento (ICP) - Ospedale dei Bambini "Vittore Buzzi" Milano - Neonatologia
    Milano, 20154, Italy
  • Policlinico Gemelli Roma - UOC Neonatologia
    Roma, 00168, Italy
08

References and documents

Publications

  • Dani C, Lista G, Bianchi S, Mosca F, Schena F, Ramenghi L, Zecca E, Vento G, Poggi C, Leonardi V, Minghetti D, Rosignoli MT, Calisti F, Comandini A, Cattaneo A, Lipone P. Intravenous paracetamol in comparison with ibuprofen for the treatment of patent ductus arteriosus in preterm infants: a randomized controlled trial. Eur J Pediatr. 2021 Mar;180(3):807-816. doi: 10.1007/s00431-020-03780-8. Epub 2020 Sep 4. PubMed 32888085 ↗
  • Dani C, Poggi C, Mosca F, Schena F, Lista G, Ramenghi L, Romagnoli C, Salvatori E, Rosignoli MT, Lipone P, Comandini A. Efficacy and safety of intravenous paracetamol in comparison to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: study protocol for a randomized control trial. Trials. 2016 Apr 2;17:182. doi: 10.1186/s13063-016-1294-4. PubMed 27038924 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2015 to primary completion in Jan 2019, 37 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2015
First posted
Apr 22, 2015
StartActual
Dec 2015
Primary completionActual
Jan 2019
CompletionActual
Apr 2019
Last update
Jul 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02422966
Responsible party
Sponsor
First posted
Apr 22, 2015
Start date
Dec 2015
Primary completion
Jan 2019
Completion
Apr 2019
Last update
Jul 12, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion